Abstract
This chapter illustrates clinical case examples demonstrating clinical utility and diagnostic performance of FDG PET-CT scans in prostate, bladder, and renal cell carcinoma.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
SEER: The Surveillance, Epidemiology, and End Results Program (http://seer.cancer.gov)-based within the Surveillance Research Program (SRP) at the National Cancer Institute (NCI).
Even-Sapir E, et al. The detection of bone metastases in patients with high-risk prostate cancer: 99mTc-MDP planar bone scintigraphy, single- and multi-field-of-view SPECT, 18F-fluoride PET, and 18F-fluoride PET/CT. J Nucl Med. 2006;47:287.
Heicappell R, et al. Staging of pelvic lymph nodes in neoplasms of the bladder and prostate by positron emission tomography with 18F FDG. Eur Urol. 1999;36:582–7.
Ahlstrom H, et al. Positron emission tomography in the diagnosis and staging of urinary bladder cancer. Acta Radiol. 1996;37:180–5.
Bachor R, et al. Lymph node staging of bladder neck carcinoma with positron emission tomography. Urologe. 1999;38:46–50.
Mantzarides M, Papathanassiou D, Bonardel G, et al. High-grade lymphoma of the bladder visualized on PET. Clin Nucl Med. 2005;30:478–80.
Shvarts O, et al. Positron emission tomography in urologic oncology. Cancer Control. 2002;9:335–42.
Steffens MG, et al. Clinical role of F-18 fluorodeoxyglucose positron emission tomography for detection and management of renal cell carcinoma. J Urol. 2002;168:2127–8.
Powles T, Murray I, Brock C, et al. Molecular positron emission tomography and PET/CT imaging in urological malignancies. Eur Urol. 2007;51(6): 1511–20.
Aide N, et al. Efficiency of [(18)F]FDG PET in characterizing renal cancer and detecting distant metastases: a comparison with CT. Eur J Nucl Med Mol Imaging. 2003;30:1236–45.
Oyama N, et al. FDG PET for evaluating the change of glucose metabolism in prostate cancer after androgen ablation. Nucl Med Commun. 2001;22:963.
Beheshti M, et al. Detection of bone metastases in patients with prostate cancer by 18F fluorocholine and 18F fluoride PET-CT: a comparative study. Eur J Nucl Med Mol Imaging. 2008;35:1766.
Jadvar H. Molecular imaging of prostate cancer with [F-18]-fluorodeoxyglucose PET. Nat Rev Urol. 2009;6:317–23.
Hamaoka T, et al. Tumor response interpretation with new tumor response criteria vs. the World Health Organization criteria in patients with bone-only metastatic breast cancer. Br J Cancer. 2010;102:651–7.
Jadvar H. Prostate cancer: PET with 18F-FDG, 18F- or 11C-acetate, and 18F- or 11C-choline. J Nucl Med. 2011;52:81–9.
Subhas N, Patel PV, Pannu HK, et al. Imaging of pelvic malignancies with in-line FDG PET-CT: case examples and common pitfalls of FDG PET. Radiographics. 2005;25:1031–43.
Kang DE, et al. Clinical use of fluorodeoxyglucose F 18 positron emission tomography for detection of renal cell carcinoma. J Urol. 2004;171:1806–69.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2016 Springer Science+Business Media New York
About this chapter
Cite this chapter
Desai, B., Jadvar, H. (2016). Urologic Neoplasms: Prostate, Bladder, and Renal Cell Carcinoma. In: Conti, P., Kaushik, A. (eds) PET-CT. Springer, New York, NY. https://doi.org/10.1007/978-1-4419-5811-2_8
Download citation
DOI: https://doi.org/10.1007/978-1-4419-5811-2_8
Publisher Name: Springer, New York, NY
Print ISBN: 978-1-4419-5810-5
Online ISBN: 978-1-4419-5811-2
eBook Packages: MedicineMedicine (R0)